NCT03869866View on ClinicalTrials.gov

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon

PHASE3CompletedINTERVENTIONAL

Enrollment

290

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions

Healthy Volunteers (Meningococcal Infection)

Interventions

BIOLOGICAL

Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine

Pharmaceutical form: Solution for injection Route of administration: Intramuscular

Trial Locations (3)

11-0236

Investigational Site Number : 4220001, Beirut

06590

Investigational Site Number : 7920002, Ankara

06800

Investigational Site Number : 7920001, Ankara

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03869866 - Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon | Biotech Hunter | Biotech Hunter